Peroxisome proliferator activated receptors

Farmacia

Volumn 58, Issue 1, 2010, Pages 13-20

  Habor, Adriana ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Glucose metabolism; Inflammatory response; Nuclear receptors; Obesity; Peroxisome Proliferator Activated Receptors (PPARs)

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; IBUPROFEN; INDOMETACIN; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG MECHANISM; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; MORPHOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SKIN DISEASE; TISSUE DISTRIBUTION;

EID: 77649206750     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Auwerx J- PPARgamma, the ultimate thrifty gene. Diabetologia, 1999, 42: 1033-1049
2. Barbier O, Duran-Sandoval D, Pineda Torra I et al- Peroxisome proliferatoractivated Receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP- glucuronosyltransferase 2B4 enzyme. J Biol Chem, 2003 Aug 29; 278 (35): 32852-32860.
3. Braissant O, Fouffelle F, Scotto C et al- Differential expression of peroxisome proliferators-activated receptors (PPARs): tissue distribution of PPAR-alfa, beta and gamma in the adult rat. Endocrinology, 1996, 137: 354-366.
4. Vanden Henvel JP- PPARs and carcinogenesis. Toxicol Sci. 1999, 47: 1-8.
5. Chinetti G, Fruchart JC, Staels B- Peroxisome proliferator-activated Receptor : new targets for the pharmacological modulation of macrophage gene expression and function. Curr Opin Lipidol, 2003 Oct; 14 (5): 459-468.
6. Berger J, Leibowitz MD, Doebber TW et al- Novel PPARgamma and PPARdelta ligands produce distinct biological effects. J Biol Chem, 2000, 274: 6718-6725.
7. Bastie C, Holst G, Gaillard D et al- Expression of peroxisome proliferatorsactivated receptor PPARdelta promotes induction of PPARgamma and adipocytes differentiation in 3T3C2 fibroblasts. J. Biol Chem, 1999, 30: 21920-21925.
8. Duval C, Chinetti G, Trottein F, Frichart JC, Staels B- The Role of PPARs in Atherosclerosis. Trends Mol Med, 2002 Sep; 8(9): 4222-4230.
9. Pineda Torra I, Gervois P, Staels B- PPAR alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol, 1999,10: 151-159.
10. Shuldiner AR, Nguyen W, Kao WH et al- Pro115Gln peroxisome proliferatorsactivated receptor-gamma and obesity. Diabetes Care, 2000, 23: 126-127.
11. Leibowitz MD, Fievet C, Hennuyer N et al- Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett, 2000, 473: 333-336.
12. Devchand PR, Keller BM, Peters JM et al- The PPARalpha-leucotriene B4 pathway to inflammation control. Nature, 1996, 384: 39-43.
13. Tanaka T, Iron H, Doi K et al- Down regulation of peroxisome proliferatoractivated receptor gamma expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia, 1999, 42:702-710.
14. Spiegelman BM. PPARgamma: adipogenic regulator and thiazolidinedione receptor. Diabetes, 1998, 47: 507-514.
15. Hu E, Kim JB, Sarraf P, Spiegelman BM- Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science, 1996, 274: 2100-2103.
16. Barroso I, Gurnell M, Crowley VV et al- Dominant negative mutation in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature, 1999, 402: 880-883.
17. Madej A, Okopein B, Kowalski J et al- Effects of fenofibrate on plasma cytokine concentration in patients with atherosclerosis and hyperlipoproteinemia IIb, Int J Clin Pharmacol Ther, 1998, 4: 1053-1057.
18. Chevillotte E, Rieusset J, Roques M et al- The regulation of uncoupling protein-2 (UCP-2) gene expression by n-6 polyunsaturated fatty acids in human skeletal muscle cells involves multiple pathways, including the nuclear receptor PPARbeta. J Biol Chem, 2001, 278: 13413-13416.
19. Rosen ED, Sarraf P, Troy AE et al- PPARgamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell, 1999, 4: 611-617.
20. Nagy L, Tontonoz P, Alvarez JGA et al- Oxidized LDL regulates macrophage gene expression througt ligant activation of PPAR gamma. Cell,1998, 93: 229-240
21. Khandoudi N, Delerive P, Berrebi-Bertrand I et al- Rosiglitazone, a peroxisome proliferator- activated receptor-gamma, inhibits the Jun NH(2)-terminal Kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes, 2002 May; 51 (5): 1507-1514.
22. Lefevre P, Chinetti G, Fruchart JC, Staels B- Sorting out the roles of PPARs in energy metabolism and vascular homeostasis. The journal of Clinical Investigation, 2006, 116 (3): 571-581.
23. Anne Rubenstrunk, Hanf R, Hum DW, Fruchart JC- Safety issues and prospects for future generations of PPAR modulators. Biochimica et Biophysica Acta, 2007; 1771: 1065-1081.
24. Tsujii M, Kawano S, Tsujii S, Sawaoka H et al- Cyclooxygenase regulates angiogenesis induces by colon cancer cells. Cell, 1998, 93: 705-716.
25. Fruchart JC and Duriez P- Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism, Drugs Today (Barc), 2006, 42 (1): 39-64.
26. Martin-Nizard F, Furman C, Delerive P, Kandoussi A et al- Peroxisome proliferator-activated Receptor Activators Inhibit Oxidized Low-density Lipoprotein-induced Endothelin-1 Secretion In Endothelial Cells. J Cardiovasc Pharmacol, 2002 Dec; 40 (6): 822-831.
27. Delerive P, Martin-Nizard F, Chinetti G et al- PPAR activators inhibit thrombininduced endotelin-1 production in human vascular endothelial cells by inhibiting the AP-1 signaling pathway. Circ Res, 1999,85: 394-402.
28. Mohora M., Greabu M., Redox sensitive signaling factors and antioxidants, Farmacia, 2009, 57(4), 399-410
29. Paumelle R, Blanquart C, Briand O et al- Acute Anti-inflammatory properties of stanins involve PPAR alpha via inhibition of the PKC signalling pathway, Circ Res 2006; 98 (3): 361-369.
30. Gizard F, Barbier O, Bellosta S et al- PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor gene p16/Nk4a. J.Clin. Invest, 2005; 115: 3228-3228.
31. Elod Nagy, Oşanu A., Clinical study regarding the relationship between lipoprotein (a) and C reactive protein serum levels in peripheral arterial disease, Farmacia, 2009, 57(1), 43- 51
32. Desreumaux P, Ernst O, Geboes K et al- Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology, 2000, 117: -73-81.